CPhI NEWS: ICSE to be launched in the US in 2012
ICSE Europe visitors targeting North America region for the development of business over the next three years
CPhI Worldwide organiser UBM Live is to launch ICSE USA next year in Philadelphia. The new event will be held from 22 - 23 May 2012 at the Pennsylvania Convention Centre and will focus on the pharmaceutical contract services and outsourcing sectors in the US market.
The introduction of ICSE USA in 2012 comes as a direct response to feedback from 60.2% of ICSE Europe 2010 visitors, who indicated that the North America region is their strongest target for the development of business over the next three years. The exhibitor profile will include companies specialising in custom manufacturing, biotechnology, clinical trials from phase I to IV, IT services, contract research, drug discovery, laboratory services, logistics services, marketing services and r&d. ICSE USA will also offer educational sessions and networking opportunities.
ICSE USA will run simultaneously with Pharmapack North America, another new event hosted by UBM that will focus on drug devices, delivery systems and packaging solutions, as well as East Pack, which offers the premier industry resource for East Coast packaging and manufacturing sectors. The events will also be collocated with Medical Design & Manufacturing (MD&M) East, the longest running medical design and manufacturing event in the world. The combined events will capitalise on cross over traffic and the synergies between the shows with the aim of strengthening existing relationships while creating additional business opportunities for attendees and exhibitors alike.
‘As US companies race against the expiration of blockbuster drugs, there has been a huge push towards the development of biosimilars and biologics to fill the needs of the market,’ said Haf Cennydd, global brand director of ICSE. ‘Coupled with the introduction of the Patient Protection and Affordable Care Acts, which highlight the need to make quality pharmaceuticals more accessible to all citizens, these factors have created a massive drive for r&d in the US market. Running r&d and clinical trials in the US is expensive and directly increases the demand for comprehensive contract and outsourcing resources in this market.’
